A computational combinatorial approach identifies a protein inhibitor of superoxide dismutase 1 misfolding, aggregation, and cytotoxicity

Received for publication, April 3, 2017, and in revised form, July 21, 2017. Published, Papers in Press, August 2, 2017, DOI 10.1074/jbc.M117.789610

Victor Banerjee, Ofek Oren, Efrat Ben-Zeev, Ran Taube, Stanislav Engel, and Niv Papo

From the Department of Biotechnology Engineering and the National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel, the Department of Clinical Biochemistry and Pharmacology and the National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel, the Shraga Segal Department of Microbiology, Immunology, and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel, and the Nancy and Stephen Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science, Rehovoth 76100, Israel

Edited by Wolfgang Peti

Molecular agents that specifically bind and neutralize misfolded and toxic superoxide dismutase 1 (SOD1) mutant proteins may find application in attenuating the disease progression of familial amyotrophic lateral sclerosis. However, high structural similarities between the wild-type and mutant SOD1 proteins limit the utility of this approach. Here we addressed this challenge by converting a promiscuous natural human IgG-binding domain, the hyperthermophilic variant of protein G (HTB1), into a highly specific aggregation inhibitor (designated HTB1M) of two familial amyotrophic lateral sclerosis–linked SOD1 mutants, SOD1G93A and SOD1G85R. We utilized a computational algorithm for mapping protein surfaces predisposed to HTB1 intermolecular interactions to construct a focused HTB1 library, complemented with an experimental platform based on yeast surface display for affinity and specificity screening. HTB1M displayed high binding specificity toward SOD1 mutants, inhibited their amyloid aggregation in vitro, prevented the accumulation of misfolded proteins in living cells, and reduced the cytotoxicity of SOD1G93A expressed in motor neuron–like cells. Competition assays and molecular docking simulations suggested that HTB1M binds to SOD1 via both its α-helical and β-sheet domains at the native dimer interface that becomes exposed upon mutated SOD1 misfolding and monomerization. Our results demonstrate the utility of computational mapping of the protein–protein interaction potential for designing focused protein libraries to be used in directed evolution. They also provide new insight into the mechanism of conversion of broad-spectrum immunoglobulin-binding proteins, such as HTB1, into target-specific proteins, thereby paving the way for the development of new selective drugs targeting the amyloidogenic proteins implicated in a variety of human diseases.

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the loss of upper and lower motor neurons (1). About 10% of ALS cases are familial (fALS), having a genetic origin, whereas the rest are sporadic (2). About 20% of fALS cases are caused by mutations in the enzyme copper/zinc superoxide dismutase 1 (SOD1), an enzyme that reduces oxidative stress by converting reactive oxygen species into oxygen and hydrogen peroxide (2, 3). More than 150 mutations in SOD1 (either single point or deletion) have been linked to fALS (4–6). These are distributed throughout the protein sequence with no specific pattern (4, 7), and, importantly, most are associated with misfolding and aggregation of SOD1 (8–10). Even though the mechanism by which SOD1 is associated with neuron degeneration is not clear, it has been hypothesized that gain of function(s) acquired by misfolded SOD1 proteins allows them to interact with homologous (other SOD1 molecules) or heterologous (unrelated) proteins, thereby leading to misfolding and aggregation of the former and hampering the normal functions of the latter proteins (6, 8, 11–13). In the “homologous mechanism,” misfolded SOD1 induces misfolding of folded SOD1 conformers in a prion-like manner, and those misfolded conformers eventually form amyloid-like aggregate structures (7, 14, 15). Recently, we identified the aggregation-triggering segment of SOD1, “LSGDHC,” which is located in the Greek key loop. This segment is presumably exposed upon misfolding and interacts with folded SOD1 proteins to trigger aggregation (7). Interaction of misfolded SOD1 with heterologous proteins may cause toxicity by a variety of mechanisms; for example, by binding to Derlin-1, a component of the endoplasmic reticulum associated with the protein degradation pathway, and hampering its function (3, 16, 17).

This work was supported by European Research Council “Ideas Program” ERC-2013-StG Contract Grant 336041 and Israel Science Foundation Grant 615/14 (to N. P.). The authors declare that they have no conflicts of interest with the contents of this article.

This article contains supplemental Figs. S1–S10, Tables S1–S4, and Experimental Procedures.

1 To whom correspondence should be addressed: Dept. of Biotechnology Engineering and the National Institute of Biotechnology, Ben-Gurion University of the Negev, P. O. Box 653, Beer-Sheva 84105, Israel. Tel.: 972-50-2029729; E-mail: papo@bgu.ac.il.

2 The abbreviations used are: ALS, amyotrophic lateral sclerosis; fALS, familial amyotrophic lateral sclerosis; SOD, superoxide dismutase; YSD, yeast surface display; SMD, steered molecular dynamics; SPR, surface plasmon resonance; EGF, enhanced GFP; EBP, enhanced blue fluorescent protein; IRES, internal ribosome entry site; ThT, thioflavin T; TEM, transmission electron microscopy; AAV, adeno-associated virus; RC, resistance coefficient; PE, phycoerythrin; BGU, Ben-Gurion University of the Negev; DMSU, DNA Microarray and Sequencing Unit; NIBN, National Institute for Biotechnology in the Negev.
Development of a selective fALS-linked SOD1 inhibitor

Similarly, in the mitochondrial compartment, misfolded SOD1 may interact with voltage-dependent anion channel 1 (VDAC1), Bcl-2, and other protein import machinery of the mitochondria, thereby altering their functions (13). Thus, inhibition of misfolding and subsequent aggregation of SOD1 appears to be of paramount importance for preventing the toxicities associated with both homologous and heterologous interaction pathways (3, 18, 19).

SOD1G93A is the most extensively researched fALS-linked mutant of SOD1, being studied in both cellular and animal ALS models (3, 7, 20, 21). Nevertheless, there are only a few reports of development of molecular agents targeting SOD1G93A for the treatment of ALS, and none has yet been approved by the Food and Drug Administration. A few compounds have been reported to extend the life of transgenic SOD1G93A mice by 10–15%, but, likewise, none of these have been successfully translated into a treatment for fALS (22, 23). To date, there are only two Food and Drug Administration-approved drugs for ALS, Rilutek (riluzole) and Radicava (edaravone), and these drugs are not curative; they merely marginally slow disease progression (24). Among the few compounds that are in phase III trials, dexpramipexole and ceftarixone failed to slow disease progression, and CK2017357 is still under examination (25–28). Therefore, there is a pressing need for new therapeutics that will halt or significantly slow the progression of the disease.

With the aim to target SOD1 misfolding and aggregation, some studies have used in silico approaches to develop therapeutic agents (29–31). For example, the computational approach of Ray et al. (30) yielded several small molecules that stabilized the SOD1 dimer interface, but their role in inhibiting SOD1 aggregation was not determined. We and others have applied different methods with the aim to develop molecules that inhibit the aggregation of SOD1 (7, 31, 32). Benmouamed et al. (31), for example, used a cell-based screening approach to identify several small molecules that inhibit the aggregation of SOD1G93A. However, their most potent compound increased the life span of SOD1G93A transgenic mice by no more than 13% compared with untreated mice, again exemplifying the need for better therapeutics for fALS (33). Using phage display, Ghadge et al. (32) evolved a single-chain variable fragment to bind SOD1 proteins and showed that the evolved variants prevented the aggregation and cytotoxicity of the SOD1A4V mutant form in NSC-34 cells. However, the evolved variants did not display specificity for misfolded SOD1, as it also bound to SOD1WT, thereby limiting their application as therapeutics. Moreover, antibodies generated against the SOD1 dimeric interface did not increase the life span of ALS mice by more than 13%, probably because their large size limited their penetration into motor neuronal cells (34). Recently, using a novel computational analysis of the dynamics of protein surfaces, we identified a 20-amino acid SOD1-derived peptide (designated SE-12) that prevented amyloid aggregation of SOD1 mutants (7). Nevertheless, the need for a high inhibitor to SOD1 ratio and the self-aggregation propensity of this peptide limit its application as a drug candidate.

In this study, we sought to improve the efficiency of the individual experimental and computational approaches by employing a combined strategy in which a quantitative screening approach for selecting desirable features was complemented with computational analysis to map the interaction-prone regions of a starting protein scaffold (35, 36). The scaffold chosen was HTB1, a 58-residue hyperthermophilic variant of protein G (3, 37–39). Being a small, compact protein that is stabilized by a hydrophobic core, HTB1 possesses high thermal and chemical stabilities. An additional advantage of this protein is that the residues within both its α-helix and β-sheet regions in HTB1 are highly tolerant to substitution or incorporation of additional amino acids (37, 40, 41). A backbone dynamics analysis of the HTB1 surface revealed 12 positions within the α-helix and β-sheet regions in which intermolecular contacts would be expected to have the strongest impact on binding affinity. Based on these positions, a focused HTB1 library was constructed and screened using a yeast surface display (YSD) platform. The screening yielded HTB1M, a selective binder of two fALS-related mutants, SOD1G93A and SOD1G85R. Here we show that HTB1M prevented amyloid aggregation and inhibited misfolding and cytotoxicity of SOD1G93A in cellular ALS models.

Results
Design of the focused HTB1 mutant library

To develop molecular agents that would specifically target misfolded SOD1 mutant proteins, we applied a combinatorial affinity maturation technique using YSD (38, 39). With this technique, a combinatorial library of a protein of interest, randomized at specified positions, is expressed on the surface of yeast as a C-terminal fusion to the yeast Aga2p protein (42), and the clones are then screened for improved molecular features, such as target affinity, by using FACS (43).

In this study, HTB1 (37) served as the YSD scaffold to produce a focused HTB1 mutant library that allowed us to cover most of the sequence space for the randomized HTB1 positions. Specifically, we used a recently developed computational algorithm based on a steered molecular dynamics (SMD) simulation to map the dynamic landscape of the HTB1 surface (35, 44). The algorithm identifies surface areas that contain clusters of static residues, the so-called “stability patches.” Intermolecular interactions that involve contact residues positioned within the stability patches are expected to make a greater contribution to the binding free energy of the complex than the residues positioned within mobile surface region (35). We hypothesized that, by focusing our library on the residues within the existing stability patches, the probability of identifying efficient HTB1 binders would increase. The clusters of static residues on the HTB1 surface comprised Lys-6, Ile-8, Ala-26, Glu-27, Glu-29, Lys-30, Ile-31, Lys-33, Tyr-35, Glu-44, Lys-52, and Thr-55; of these, Lys-6, Ile-8, Glu-44, Lys-52, and Thr-55 belong to the β-sheet region and the rest to the α-helix region (Fig. 1). These residues were subjected to randomization using an assembly PCR technique, yielding a stability patch–focused library with a diversity of about 3 × 10⁵ clones. The library was used as the starting point for affinity maturation by YSD.
Affinity maturation of the HTB1 library

HTB1 and the mutated HTB1 library were expressed on the yeast surface as cMyc–HTB1 fusion proteins. The high level of expression of wild-type HTB1 was confirmed by using anti-cMyc antibodies (supplemental Fig. S1B), and its proper folding was confirmed by using human IgG antibody, a natural binder for HTB1 (45) (Fig. S1C). As expected, the displayed wild-type HTB1 scaffold did not show any affinity for SOD1G93A (supplemental Fig. S1D).

Initial sorting of the HTB1-focused library based on the expression of the C terminus c-Myc epitope produced the S₀ library, comprising only highly expressed, intact HTB1 clones (Fig. 1G). The S₀ library was then subjected to four sequential rounds of sorting for high-affinity binders, starting with 10 μM of fluorescently labeled SOD1G93A (Fig. 1I) and decreasing the concentration of the soluble SOD1G93A protein in each sorting step as described in the legend for Fig. 1, J–M. Single clones selected from the final sorting were propagated, and genomic DNA was extracted and sequenced, yielding a single HTB1 clone, designated HTB1M, with an affinity of 2.8 μM for SOD1G93A when HTB1M was displayed on yeast (supplemental Fig. S2A). This HTB1M mutant had 12 point mutations in the randomized regions and one additional mutation, K15I, added during PCR amplification.
Development of a selective fALS-linked SOD1 inhibitor

HTB1M binds SOD1G93A and SOD1G85R but not folded wild-type SOD1

HTB1M was expressed on the yeast surface and tested for binding to 2 μM soluble SOD1G93A, SOD1G85R, or wild-type SOD1 (SOD1WT) (Fig. 2, A–C). The two SOD1 mutants bound to HTB1M to a similar extent, whereas SOD1WT did not bind (Fig. 2, A–C). When SOD1WT was heated at 94 °C for 30 min and cooled down to room temperature (without causing precipitation), this thermally treated SOD1WT bound very strongly to HTB1M but not to HTB1 (Fig. 2D). To determine whether this effect was specific to SOD1 and not caused by nonspecific interactions with exposed hydrophobic patches resulting from thermal denaturation, we tested the binding of HTB1M to similarly treated bovine serum albumin or ovalbumin (chicken egg white). No binding to either of these proteins was detected (supplemental Fig. S3). The above findings show that HTB1M binds to a specific region that is buried in SOD1WT but becomes exposed because of thermal denaturation or mutation (G93A or G85R (46, 47)) of this protein. It is possible that HTB1M binds to structurally destabilized SOD1 mutants or thermally denatured SOD1 through the exposed dimer interface. To test this idea, we incubated SOD1 mutant proteins with SPC-206 (48), a monoclonal antibody that specifically binds to the dimeric interface of SOD1, prior to SOD1 binding to HTB1M. As shown in supplemental Fig. S2, B and C, the SPC-206 mAb did indeed compete with HTB1M for binding to SOD1 mutants, thereby supporting our hypothesis that HTB1M interacts with the exposed dimeric interface of SOD1.

To further elucidate the binding interaction of HTB1 and HTB1M with SOD1, both HTB1 and HTB1M were purified from Escherichia coli strain BL21 DE3. The molecular masses (obtained by MALDI-TOF) of pure HTB1 and HTB1M monomers were 8.7 and 8.9 kDa, respectively, which matched the theoretical molecular mass of these proteins (supplemental Fig. S4, B and C). Size-exclusion chromatography analysis under native conditions revealed that purified HTB1 was a monomer, whereas HTB1M existed as oligomer (supplemental Fig. S4A). Both proteins had a tryptophan fluorescence emission maximum at around 337 nm, indicating that they are folded under physiological conditions (supplemental Fig. S4D). (We note that tryptophan fluorescence spectra are an accepted tool for studying protein folding (49, 50).)

The binding of purified HTB1 and HTB1M proteins to SOD1WT or the SOD1 mutants SOD1G93A and SOD1G85R was determined with surface plasmon resonance (SPR) spectroscopy. As expected, correctly folded HTB1 efficiently bound IgG (supplemental Fig. S5A) but not SOD1WT, SOD1G93A, or SOD1G85R (supplemental Fig. S5, B–D). Unlike HTB1, HTB1M did not show any affinity for IgG (supplemental Fig. S6A), probably because of the mutations in its α-helix domain that harbor the IgG binding epitope (45). HTB1M, however, efficiently bound SOD1G93A and SOD1G85R with calculated equilibrium binding constants of 300 and 674 nM, respectively (Fig. 2, A–C). The binding of HTB1M to SOD1G93A–enhanced GFP (EGFP) was not observed up to a concentration of 600 nM (Fig. 2G).

To determine whether the same epitope of HTB1M is used for interaction with the two SOD1 mutants, SOD1G93A and SOD1G85R, we performed a competitive binding assay. Satura-

Docking analysis of HTB1M with wild-type SOD1 and SOD1 mutants

To acquire insight into the binding mode of HTB1M to SOD1, we used computational docking analysis. The structure...
of HTB1\textsubscript{M} was generated by homology modeling based on the published structure of the B1 domain of protein G (supplemental Fig. S8, A–C) (51). We used the homology modeling under the assumption that the inability of HTB1\textsubscript{M} to bind IgG was due to the mutations in the \(\alpha\)-helix IgG binding domain of the former and not due to global structural perturbations. The HTB1\textsubscript{M} modeled structure was then docked with SOD1\textsuperscript{G93A} and SOD1\textsuperscript{G85R}.

Selection of the best docking solutions was made on the basis of ZRANK score, cluster size, nature of the interface, and type of interactions in each complex together with the available biological information (see “Experimental Procedures”). ZDOCK docking poses solutions were clustered according to the ligand position, and analysis of the top poses of the largest clusters indicated the preferred interfaces (supplemental Fig. S8E). Based on the experimental finding indicating that HTB1\textsubscript{M} binds at the SOD1 native dimer interface, we focused on the cluster that shares the same interface with the SOD1\textsuperscript{WT} homodimer.

A comparison between the docking results for HTB1\textsubscript{M} with the two SOD1 mutants showed that the HTB1\textsubscript{M}/SOD1\textsuperscript{G93A} complex gave a better docking score and ranking than the docking solution to SOD1\textsuperscript{G85R} (supplemental Table S1), in keeping with the experimental results; the various types of HTB1\textsubscript{M}–SOD1 interactions are shown in supplemental Tables S2 and S3. In addition, the cluster size and cluster density of the HTB1\textsubscript{M}–SOD1\textsuperscript{G93A} complex were higher, indicating that more docking solutions were obtained for this interface (supplemental Table S1). These differences in the number of docking solutions might reflect the fact that there are certain differences in the conformers of SOD1 side chains at the complex interface in SOD1\textsuperscript{G93A} versus SOD1\textsuperscript{G85R} (supplemental Fig. S8F and Table S2). In G93A and G85R, the mutations are not located in the predicted interface HTB1\textsubscript{M}–SOD1 binding site, and, hence, their influence on the binding is minor, if any.

Our detailed analysis of the mutated HTB1\textsubscript{M} residues positioned on the putative SOD1\textsuperscript{G93A}–HTB1\textsubscript{M} complex interface revealed that Arg-29 in HTB1\textsubscript{M} makes the highest contribution to the polar contact surface area and that Phe-44 and Ile-33 contribute to the nonpolar contact surface area (Fig. 3A). Although Arg-29 and Ile-33 mutations are located on the \(\alpha\)-helix domain of HTB1\textsubscript{M}, the Phe-44 mutation is located on the \(\beta\)-strand. Thus, it appears that both the \(\alpha\)-helical and \(\beta\)-sheet structural domains of HTB1\textsubscript{M} contribute to the interaction with SOD1. To validate our docking model, we made three single point mutants, HTB1\textsubscript{M}\textsuperscript{R29E}, HTB1\textsubscript{M}\textsuperscript{I33K}, and HTB1\textsubscript{M}\textsuperscript{F44E} (positions 29, 33, and 44 were changed back to the residues HTB1 has in those positions), and studied the binding of three mutants to SOD1\textsuperscript{G93A} and SOD1\textsuperscript{G85R} in YSD (Fig. 3, B and C). The HTB1\textsubscript{M}\textsuperscript{R29E} mutant showed slightly higher binding than HTB1\textsubscript{M}, as expected from the docking model in which Arg-29 is in close proximity to Lys-9 of SOD1, and replacing Arg with Glu may create a salt bridge that facilitates binding (Fig. 3A, left panel). The other two mutants showed lower affinity for SOD1 mutants. Replacing Ile-33 with Lys (HTB1\textsubscript{M}\textsuperscript{I33K} mutant) may cause repulsion between Lys-33 of HTB1\textsubscript{M}\textsuperscript{I33K} and Lys-9 of SOD1, and this repulsion could account for the lower binding of HTB1\textsubscript{M}\textsuperscript{I33K} to the SOD1 mutant (Fig. 3A, left panel, B, and C).

Phe-44 is situated in close proximity to Asp-52 of SOD1, and this repulsion could account for the lower binding of HTB1\textsubscript{M}\textsuperscript{F44E} to the SOD1 mutant (Fig. 3, B and C).

HTB1\textsubscript{M} inhibits amyloid-like aggregation of SOD1 mutants in vitro

We next investigated the effect of HTB1\textsubscript{M} on mutant SOD1 amyloid-like aggregate formation. To this end, we allowed SOD1\textsuperscript{G85R} or SOD1\textsuperscript{G93A} (50 \(\mu\)M) to aggregate in the presence of different concentrations of HTB1\textsubscript{M}. Aggregate formation was followed by monitoring the fluorescence of thioflavin T (ThT) dye, which specifically interacts with amyloid-like aggregates (52). Our results showed that HTB1\textsubscript{M} inhibited aggregation of the SOD1 mutants at a concentration-dependent manner (Fig. 4). Notably, a substoichiometric amount of HTB1\textsubscript{M} was able to inhibit the aggregation of both SOD1\textsuperscript{G93A} and SOD1\textsuperscript{G85R} (Fig. 4, A and B). In contrast, HTB1 did not inhibit aggregation of the SOD1 mutants (Fig. 4, A and B). In addition, HTB1 and HTB1\textsubscript{M}, when tested alone, did not show any significant ThT response, thereby indicating a lack of amyloid-like fibril formation under aggregation-promoting conditions (Fig. 4B).

Transmission electron microscopy (TEM) showed that fibrils formed by SOD1\textsuperscript{G93A} and SOD1\textsuperscript{G85R} in the presence or
absence of HTB1 were of similar width (10–12 nm), indicating that HTB1 did not have any effect on the morphology of the aggregates that were formed (Fig. 4, C and D). In contrast, no such fibrils were observed for the SOD1 mutants incubated with HTB1M in a 1:2 molar ratio (SOD1:HTB1M) (Fig. 4, C and D). However, even though HTB1M prevented the formation of ordered amyloid-like fibrils, it could not prevent the appearance of some amorphous aggregates of the SOD1 mutants (Fig. 4, C and D).

**HTB1M suppresses misfolding of SOD1G93A in the cytosol of motor neuron–like NSC-34 cells**

To examine whether HTB1M can attenuate the misfolding of the SOD1G93A mutant in cells, we co-expressed SOD1G93A-EGFP and HTB1M-IRES-EBFP proteins (in 1:0.5 and 1:1 SOD1G93A:HTB1M DNA concentration ratios) in motor neuron–like NSC-34 cells. Comparable transfection efficiencies were verified by measuring the fluorescence intensity of both EGFP and EBFP by FACS; as shown, high expression levels were found for both SOD1G93A and HTB1M (supplemental Fig. S9).

In the absence of HTB1M, misfolded SOD1G93A accumulated in the cytosol, as identified by IP with B8H10 antibody, which specifically recognizes the misfolded SOD1 conformation (3, 53), followed by Western blotting with a C-17 antibody for SOD1. HTB1M co-transfected with SOD1G93A reduced the levels of misfolded SOD1G93A in a dose-dependent manner without affecting the overall expression levels of SOD1G93A (Fig. 5). At a 1:1 SOD1G93A:HTB1M DNA ratio, the accumulation of misfolded SOD1G93A was around 60% of the amount observed in the absence of HTB1M (Fig. 5).

**HTB1M reduces SOD1G93A-induced toxicity in NSC-34 cells**

Misfolded or aggregated SOD1 mutants are believed to be major cause of motor neuron degeneration in ALS. Our obser-
SOD1WT had a minimum effect on cell survival, but SOD1G93A/a1/H9262 on cell survival. Recent studies have shown that these aggregates may be the major cause of the damage to motor neurons (60, 61). In particular, these aggregates may elicit cellular toxicity in fALS patients by hampering the nuclear export and import system (19, 53, 60, 62). Mutant SOD1 is, therefore, a potential target in the search for fALS therapeutics. In this study, we developed a novel inhibitor, HTB1M, that exhibits specificity toward SOD1 mutants and prevents their misfolding and aggregation both in vitro and in cells, thus providing a foundation for the development of new ALS therapeutics.

### Development of a selective fALS-linked SOD1 inhibitor

To maximize the likelihood of achieving desirable properties for the YSD-engineered protein, in terms of both binding affinity and selectivity, we used a focused library, the construction of which was guided by a computational analysis of the HTB1 sequence space for the randomized positions but small enough is sufficiently large to cover a considerable portion of the sequence space for the randomized positions but small enough to be tractable by the YSD technique.

According to our molecular docking results, among the residues randomized in HTB1, Arg-29 and Ile-33 in the α-helix domain and Phe-44 in the β-sheet domain are predicted to play a central role in the interaction with SOD1 (Fig. 3). Smith et al. (41) evolved the same scaffold (HTB1; in their case, to bind amyloid β-40 peptide), but they mutated only the β-sheet domain. In contrast, assuming that both the α-helix and β-sheet domains may contribute to the interaction with SOD1, we mutated both domains. In addition, position 31 was mutated from isoleucine in HTB1 to proline in HTB1M. This mutation is predicted to cause a break in the α-helix secondary structure of HTB1M (supplemental Fig. S8, C and D), which might be one of the reasons why HTB1M does not interact with human IgG but HTB1 does. The results of both docking and competitive YSD binding experiments are consistent with the
idea that HTB1M uses the same binding epitope (predicted to comprise both the α-helix and β-sheet domains) to interact with the two structurally and functionally different mutants, SOD1G93A and SOD1G85R (Figs. 2H and 3).

Under normal physiological conditions, SOD1 is a homodimeric protein (32 kDa), but under certain conditions, such as elevated temperature and/or a mutation, the protein monomer–dimer equilibrium may be shifted toward the monomeric state, exposing the dimer interface (47, 63). Indeed, the results of a competitive binding experiment using the SPC-206 mAb, whose binding epitope is located within the native SOD1 dimer interface, and in silico HTB1M–SOD1 docking suggest that HTB1M binds to the native dimer interface of SOD1, which appears to be accessible in the SOD1 mutants but is hidden in SOD1WT, thereby providing the basis for the HTB1M binding selectivity. Our experimental results indicate that HTB1M binding thermodynamically stabilizes mutant SOD1 proteins (supplemental Fig. S10 and Table S4), which may lead to their enhanced solubility and a reduced propensity to form potentially toxic amyloid aggregates. It is also possible that interaction with HTB1M sterically interferes with the formation of aberrant SOD1 complexes.

One of the main problems in developing treatments for CNS diseases is delivery of the therapeutic agent to the CNS. However, recent progress in vector-mediated drug delivery has made it possible to exploit this type of biotechnology in the treatment of various CNS diseases (64). Of particular relevance to our study are clinical trials showing a significant safety margin for the adeno-associated virus (AAV) vector in delivery into the brain of therapeutics for Alzheimer’s, Parkinson’s, Canavan, and Batten diseases (65–67). AAV, with its inherent advantage of long-term expression of the desired gene without deleterious inflammatory response, would be our choice of vehicle to test HTB1M as a therapeutic agent. Previous work on AAV-mediated delivery of a single-chain variable fragment in an ALS mouse model has shown sustained expression of the antibody in the spinal cord, leading to an extension of around 28% of the life span of the mice (68).

In conclusion, we demonstrated that HTB1M acts as a specific inhibitor that reduces the extent of both misfolding and aggregation of SOD1 ALS mutants in stoichiometric concentrations and decreases SOD1G93A-induced toxicity to motor neuron–like cells. We also showed that the HTB1 scaffold is well suited for the design of high-affinity and specificity precursors for ALS therapeutics. Our unique approach of combining computational and directed evolution methods for protein engineering can potentially be extended to other proteins that form amyloids, thereby increasing the availability of anti-fibril therapeutics.

**Development of a selective fALS-linked SOD1 inhibitor**

The HTB1 gene, codon-optimized for *Saccharomyces cerevisiae*, was purchased from Integrated DNA Technologies and inserted into *S. cerevisiae* strain EBY-100 via homologous recombination as described previously (72, 73). Generation of the rational and combinatorial HTB1 library is described in detail in the supplemental Experimental Procedures. In brief, 12 residue positions were selected based on the SMD simulation, as described above, and the library was created by assembly PCR with primers having NNS (N = Ala, Cys, Thr, or Gly; S = Cys or Gly) at the specific positions. The resulting DNA library was amplified and transformed into *S. cerevisiae* strain EBY-100 through homologous recombination. The size of the HTB1 focused library was about $3 \times 10^5$, with 12 mutations per clone.

**Flow cytometry and cell sorting**

The yeast-displayed HTB1 library and individual HTB1 variants were grown in SDCAA-selective medium (as for SDCAA plates but without agar, see supplemental Experimental Procedures) and induced for expression with galactose medium (as for SDCAA but with galactose instead of dextrose), according to established protocols (73, 74). In the first step, ~$1 \times 10^6$ cells were incubated with different concentrations of biotinylated target SOD1G93A for 2 h together with a 1:100 dilution of chicken anti-c-Myc IgY antibody (Abcam) in PBST buffer (1× PBS, 50 mM NaCl, and 0.05% Tween 20). Thereafter, cells were washed with PBST and incubated with FITC-conjugated NeutrAvidin (Thermo Fisher Scientific, 1:800 dilution) and phycocyanin (PE)-conjugated goat anti-chicken IgY (Santa Cruz Biotechnology, 1:100 dilution) for 1 h. Cells were washed again and analyzed by dual-color flow cytometry (Accuri C6, BD Biosciences). Cell sorting was carried out with a BD FACSaria III (Ilse Katz Institute for Nanoscale Science and Technology, Ben-

**Experimental procedures**

**SMD analysis and selection of HTB1 positions for randomization and library construction**

The solution NMR structure (model 1) of HTB1 (PDB code 1GB4) was solvated in a water box (using 8-Å padding) with sodium/chloride for charge neutralization by using the VMD program (69). The system was minimized and equilibrated by a molecular dynamics simulation, with spatial constraints applied first to the entire protein (water equilibration, 200 ps), then only to the backbone atoms (100 ps), and finally without any spatial constraints (100 ps). These and subsequent simulations were performed in an isothermal–isobaric (NPT) ensemble at 310 K using the NAMD 2.9 program and the CHARMM27 force field for proteins (70, 71). The surface-exposed residues of the equilibrated HTB1 structure were subjected to SMD analysis, essentially as described previously (35), using a flexible hemisphere of 13-Å radius surrounding the SMD atoms. For each residue, the SMD simulation was repeated 12 times, and applied forces computed from the trajectories were plotted versus distances traveled by the dummy atoms. The average slopes were calculated by applying linear regression analysis (with Prism 6, GraphPad Software, Inc.) and were referred to as the resistance coefficients (RCs) (35). The total scale of RCs (expressed in piconewton (pN) per angstrom) was divided into equal intervals to which numbers 1 to 8 were assigned, corresponding to the highest and lowest backbone mobility, respectively. The positions harboring static residues (RC ≥ 6) were selected for randomization to yield a stability-patch–focused library of HTB1 variants to be displayed on the yeast surface.
Gurion University of the Negev (BGU)). In brief, ∼1 × 10⁸ cells were first sorted to select for high-expressing clones (positive for anti-c-Myc antibody). Sorted cells were then grown in selective medium, and several colonies were sequenced DNA Microarray and Sequencing Unit (DMSU), National Institute for Biotechnology in the Negev (NIBN), BGU. Following each sorting, the number of yeast cells used for the subsequent sorting was at least 10-fold in excess of the number of sorted cells. Several clones from each round of sorting were sequenced (DMSU, NIBN, BGU) using a protocol established previously (72). Selected clones were expressed and purified from Bl21 DE3 E. coli bacterial cells as described in the supplemental Experimental Procedures.

**SPR spectroscopy**

The constants for binding of HTB1M to SOD1G93A and SOD1G85R were determined by SPR spectroscopy on a ProteOn XPR36 (Bio-Rad) as follows. HTB1M and HTB1 were immobilized on the surface of the chip by using the amine coupling reagents sulfo-NHS (0.1 M N-hydroxysuccinimide) and EDC (0.4 M 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide, Bio-Rad). The proteins (1 μg) were each covalently immobilized on the chip in 10 mM sodium acetate buffer (pH 4.0), to give 2100 and 2204 response units for HTB1M and HTB1, respectively. BSA (3 μg, 4016 response units) was immobilized on the chip as a negative control. Unbound esters were deactivated with 1 M ethanolamine HCl at pH 8.5. Before each binding assay, the temperature was set at 25 °C. Soluble human SOD1 mutants and wild-type SOD1 (the analytes) were then allowed to flow over the surface-bound HTB1M and HTB1 separately at concentrations of 39, 78.1, 156.3, 312.5 and 625 nM and a flow rate of 50 μl/min. While the analyte was flowing over the surface (for 8 min), the interactions between HTB1M and SOD1 proteins were determined. The next step was to examine the dissociation of the proteins while allowing PBST to flow over the surface for 11 min at 50 μl/min. After each run, a regeneration step was performed with 50 mM NaOH at a flow rate of 100 μl/min. For each protein complex, a sensorgram was generated from the response units measured during the course of the protein–protein interaction minus the values of the BSA background channel. The dissociation constant (K_d) was determined from the sensorgram of the equilibrium binding phase.

**Molecular modeling**

The human homology models of HTB1M were prepared with the Discovery Studio 4.5 Homology Model module (Biovia, Dassault Systemes, San Diego, CA) using the published structures of HTB1 (PDB codes 1GB4, 2ON8, and 2ONQ) as the template. The HTB1M sequence was aligned to the template structures using the Align Sequence to Templates module, and the Built Homology Model module was built based on this structural alignment. The ψ and φ torsion angles of the predicted model were computed by using Ramachandran plots, as updated by Richardson and co-workers (75). The models were verified with the Verify Protein (MODELLER) module. The discrete optimized protein energy (DOPE) score and normalized DOPE score were calculated for each structure. In addition, the probability density function (PDF), PDF total energy, and PDF physical energy were taken into consideration. The final model exhibited the highest profile 3D score (76) and the lowest number of Ramachandran violations (75). The models were eventually refined by energy minimization using the CHARMM force field (77).

**Molecular protein–protein interaction docking**

Molecular protein–protein docking of the HTB1M structure to two SOD1 mutant proteins (G93A protein (PDB code 3GZO) and G85R protein (PDB code 2ZKW)) was carried out in Discovery Studio 4.5 (Biovia, Dassault Systemes) with ZDOCK, which is a rigid-body docking program that predicts the structure of a number of protein complexes. ZDOCK uses a simple shape complementarity method known as pairwise shape complementarity. The ZDOCK program integrates the pairwise shape complementarity scoring function for identifying docked conformations and scores hits based on atomic contact energies (higher scores are better predictions for the protein–protein complexes) (78). The ZDOCK search scheme exhaustively searched all rotational and translational spaces for HTB1M relative to SOD1 mutant protein, in which the latter is fixed at its starting orientation (from its PDB coordinates). Next, HTB1M orientations were sorted by ZRANK score method, which is used for rapidly and accurately reranking the docked protein complexes predicted by ZDOCK with the aim to pick out near-native structures (most negative score, thus favorable to binding) (79). Clustering the top 2000 orientations into groups according to their spatial proximity by using an root mean square deviation cutoff of 6 and an interface cutoff of 9 assisted us to select the promising near-native structures docking solutions to be analyzed (80, 81). The cluster size indicates the size of the cluster to which the docked protein orientation belongs. The cluster density indicates the number of docked protein poses that fall within the root mean square deviation cutoff specified for clustering. This number represents the number of neighbors used in the first stage of clustering.

**ThT aggregation assay for SOD1 mutants**

Prior to the aggregation assay, all mixtures containing the protein were filtered through a 4-mm Milli-Base (PVDF) syringe filter with a 0.2-μm pore size (Millipore). SOD1G93A or SOD1G85R (50 μM) was incubated with or without HTB1M (25–100 μM) in 200 μM of 20 mM Na+ /phosphate buffer (pH 7.4), 0.1 M NaCl, 5 mM EDTA, and 1 mM tris(2-carboxyethyl)phosphine at 37 °C with 600 rpm orbital shaking. At each time point (every 24 h), 20 μl of reaction mixture was removed and stored at 4 °C for further analysis. At the end of the experiment, all samples were analyzed for their ability to bind ThT (Sigma), an amyloid-specific fluorophore, using Infinite M1000 (Tecan) plate reader with fluorescence excitation and emission wavelengths set at 440 nm and 485 nm, respectively. Each experiment was performed in triplicate. All data points were analyzed using an unpaired t test to verify that the differences between the samples tested were statistically significant.

**TEM analysis of SOD1 fibril formation**

Samples for TEM imaging were prepared as described elsewhere (82). Briefly, at the end of the aggregation assay, 2.5-μl
samples (diluted 5-fold in Milli-Q water) were deposited on a carbon-coated copper 300 mesh. After 1 min, the excess liquid was carefully blotted onto filter paper, and the grid was held at ambient temperature for 1 min. Uranyl acetate (5 μL, 2%) was added to the grid, and, after 1 min, the excess of the salt solution was carefully removed with filter paper. The imaging was performed using a Tecnai G2 12 BioTWIN (FEI) (Ilse Katz Institute for Nanoscale Science and Technology, BGU) transmission electron microscope with an acceleration voltage of 120 kV. Different magnifications were used for visualization, depending on the size of the aggregates.

**Cell culture**

The NSC-34 neuronal cell line was a generous gift from Dr. Adrian Israelson (Faculty of Health Sciences, BGU). Cells were grown at 37 °C and 5% CO2 in DMEM supplemented with 10% tetracycline-free FBS, l-glutamine (2 mM), and penicillin (100 units/ml)/streptomycin (0.1 mg/ml) (Biological Industries). Transfection was performed by using TurboFect (Thermo) according to the protocol of the manufacturer. When co-transfections were performed, empty plasmids were transfected as controls.

**Immunoprecipitation**

The SOD1-EGFP plasmid (pEGFP-N3) was a generous gift from Dr. Adrian Israelson (Faculty of Health Sciences, BGU). We cloned the HTB1M gene into the pHAGE vector with the IRES-EBFP reporter for cell culture experiments. SOD1-EGFP-transfected NSC-34 whole-cell extracts (in the absence or presence of HTB1M co-transfection, 100 μg of the whole-cell extract) were solubilized in IP buffer (20 mM Tris-Cl (pH 7.6), 200 mM NaCl, 0.72 mM EDTA, 10% glycerol, 7 mM DTT, protease inhibitor mixture (Sigma, added fresh before use at a ratio of 1:200), and Triton X-100 (0.15%)). The solubilized fraction was incubated overnight with 88H10 (MediMabs) antibody (selective for misfolded SOD1) cross-linked previously to Dynabeads protein G (Invitrogen) according to the instructions of the manufacturer. The beads were magnetically isolated and washed three times with PBS. Samples were eluted by boiling with sample buffer. Proteins were separated on 12% SDS-PAGE gel, transferred to PVDF membranes (Trans-Blot TurboTM Midi PVDF Transfer Packs, Bio-Rad) using the Trans-Blot Turbo Transfer System (Bio-Rad), and probed with goat anti-SOD1 (C-17, Santa Cruz Biotechnology), rabbit anti HA antibody (to detect HTB1M, Abcam), and rabbit anti β-tubulin antibodies (Abcam). Horseradish peroxidase-conjugated anti-goat and anti-rabbit IgG (Abcam), respectively, were used as secondary antibodies, and their signal was detected by ECL (GE Biosciences). The experiment was performed in triplicate, and quantitative analysis (n = 3) was performed using unpaired Student’s t test, where the level of significance was taken as *, p < 0.05; **, p < 0.01; or ***, p < 0.001.

**Cell viability**

Cell viability was determined with NSC-34 cells transfected with SOD1-EGFP by using an XTT-based kit (Sigma-Aldrich) according to the protocol of the manufacturer (83). The level of transfection was calculated by FACS. SOD1WT and empty vector pHAGE served as controls for the experiment. Data for each sample were normalized according to its transfection efficiency and later normalized for the empty vector control. The data are shown as percentage control. The experiment was performed in triplicate, and quantitative analysis (n = 3) was performed by unpaired Student’s t test, where the level of significance was taken as *, p < 0.05; **, p < 0.01; or ***, p < 0.001.

**Author contributions**—V. B. and N. P. designed the research. V. B. performed and analyzed the experiments shown in Figs. 1, 2, and 4 and supplemental Figs. S1–S6 and S10 and Table S4. O. O. performed and analyzed the experiments shown in Fig. 6 and supplemental Figs. S7 and S9. V. B. and O. O. together performed and analyzed the experiment shown in Figs. 3, B and C, and Fig. 5. E. B. Z. performed and analyzed the experiments shown in Fig. 3A and supplemental Fig. S8 and Tables S1–S3. V. B., O. O., E. B. Z., R. T., S. E., and N. P. analyzed data. V. B. and N. P. wrote the paper. All authors edited the manuscript and approved the final version.

**Acknowledgments**—We thank Dr. Alon Zilka, Dr. Upcher Alexander, and Itay Cohen for technical assistance.

**References**

1. Leigh, P. N. (1991) Amyotrophic lateral sclerosis and other motor neurone diseases. *Curr. Opin. Neurol. 4*, 586–596
2. Abel, O., Powell, J. F., Andersen, P. M., and Al-Chalabi, A. (2012) ALSoD: a user-friendly online bioinformatics tool for amyotrophic lateral sclerosis genetics. *Hum. Mutat. 33*, 1345–1351
3. Israelson, A., Ditsworth, D., Sun, S., Song, S., Liang, J., Hruska-Plochan, M., McAlonis-Downes, M., Abu-Hamad, S., Zoltsman, G., Shani, T., Mal- donado, M., Bui, A., Navarro, M., Zhou, H., Marsala, M., et al. (2015) Macrophage migration inhibitory factor as a chaperone inhibiting accumulation of misfolded SOD1. *Neuron 86*, 218–232
4. Battistini, S., Giannini, F., Greco, G., Bibbè, G., Ferrera, L., Marini, V., Causarano, R., Casula, M., Lando, G., Patrosso, M. C., Caponnetto, C., Origone, P., Marocchi, A., Del Corona, A., Siciliano, G., et al. (2005) SOD1 mutations in amyotrophic lateral sclerosis. *J. Neurol. 252*, 782–788
5. Al-Chalabi, A., and Leigh, P. N. (2000) Recent advances in amyotrophic lateral sclerosis. *Curr. Opin. Neurol. 13*, 397–405
6. Zetterström, P., Graffno, K. S., Andersen, P. M., Brännström, T., and Marklund, S. L. (2011) Proteins that bind to misfolded mutant superoxide dismutase-1 in spinal cords from transgenic amyotrophic lateral sclerosis (ALS) model mice. *J. Biol. Chem. 286*, 20130–20136
7. Banerjee, V., Shani, T., Katzman, B., Vyazmensky, M., Papo, N., Israelson, A., and Engel, S. (2016) A SOD1-derived peptide inhibits amyloid aggregation of ALS SOD1 mutants. *ACS Chem. Neurosci. 7*, 1595–1606
8. Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., Caliendo, J., Bentati, A., Kwon, Y. W., and Deng, H. X. (1994) Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. *Science 264*, 1772–1775
9. Ivanova, M. I., Sievers, S. A., Guenther, E. L., Johnson, L. M., Winkler, D. D., Galaleldeen, A., Sawaya, M. R., Hart, P. J., and Eisenberg, D. S. (2014) Aggregation-triggering segments of SOD1 fibril formation support a common pathway for familial and sporadic ALS. *Proc. Natl. Acad. Sci. U.S.A. 111*, 197–201
10. Furukawa, Y. (2012) Protein aggregates in pathological inclusions of amyotrophic lateral sclerosis in Amyotrophic Lateral Sclerosis (Maurer, M. H., ed.) pp. 335–356, InTech, Rijeka, Croatia
11. Bruijn, L. I., Houseweart, M. K., Kato, S., Anderson, K. L., Anderson, S. D., Ohama, E., Reuame, A. G., Scott, R. W., and Cleveland, D. W. (1998) Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. *Science 281*, 1851–1854
12. Wong, P. C., Pardo, C. A., Borchelt, D. R., Lee, M. K., Copeland, N. G., Jenkins, N. A., Sisodia, S. S., Cleveland, D. W., and Price, D. L. (1995) An
Development of a selective FALS-linked SOD1 inhibitor

adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. 

Neuron 14, 1105–1116

13. Israelson, A., Arbel, N., Da Cruz, S., Ilieva, H., Yamanaka, K., Shoshan-Barmatz, V., and Cleveland, D. W. (2010) Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALS. 

Neuron 67, 575–587

14. Lee, S., and Kim, H.-J. (2015) Prion-like mechanism in amyotrophic lateral sclerosis: are protein aggregates the key? Exp. Neurobiol. 24, 1–7

15. Lee, S., and Kim, H.-J. (2015) Prion-like mechanism in amyotrophic lateral sclerosis: are protein aggregates the key? Exp. Neurobiol. 24, 1–7

16. Fujisawa, T., Homma, K., Yamaguchi, N., Kadowaki, H., Tsuburaya, N., Sugaya, K., and Nakano, I. (2014) Prognostic role of “prion-like propagation” in SOD1-linked familial ALS: an alternative view. Front. Cell. Neurosci. 8, 359–368

17. Nishitoh, H., Kadowaki, H., Nagai, A., Maruyama, T., Yokota, T., Fuku- tomi, H., Noguchi, T., Matsuzawa, A., Takeda, K., Ichijo, H. (2008) ALS-linked mutant SOD1 induces ER stress- and ASK1-dependent motor neuron death by targeting Derlin-1. Genes Dev. 22, 1451–1464

18. Williams, J. R., Trias, E., Beiby, P. R., Lopez, N. I., Labut, E. M., Bradford, C. S., Roberts, B. R., McAllum, E. J., Crouch, P. J., Rhoads, T. W., Pereira, C., Son, M., Elliott, J. L., Franco, M. C., Estévez, A. G., et al. (2016) Copper delivery to the CNS by CuATSM effectively treats motor neuron disease in SOD G93A mice co-expressing the copper-chaperone for-SOD. Neurobiol. Dis. 89, 1–9

19. Wang, L., Popko, B., Tixier, E., and Roos, R. P. (2014) Guanabenz, which enhances the unfolded protein response, ameliorates mutant SOD1-induced amyotrophic lateral sclerosis. Neurobiol. Dis. 71, 317–324

20. Sesso, A., Trippoli, S., Becagli, P., and Zaccara, G. (1999) Cost effective-
Development of a selective fALS-linked SOD1 inhibitor

48. Tokuda, E., Anzai, I., Nomura, T., Toichi, K., Watanabe, M., Ohara, S., Watanabe, S., Yamanaka, K., Morisaki, Y., Misawa, H., and Furukawa, Y. (2017) Immunohistochemical characterization on pathological oligomers of mutant Cu/Zn-superoxide dismutase in amyotrophic lateral sclerosis. *Mol. Neurodegener.* **12**, 2–20

49. Das, K. P., Petrosh, J. M., and Surewicz, W. K. (1996) Conformational properties of substrate proteins bound to a molecular chaperone-crystallin. *J. Biol. Chem.* **271**, 10449–10452

50. Banerjee, V., and Das, K. (2014) Structure and functional properties of a multimeric protein aα-crystallin adsorbed on silver nanoparticle surface. *Langmuir* **30**, 4775–4783

51. Salit, A., and Blundell, T. (1993) Comparative protein modelling by satisfaction of spatial restraints. *J. Mol. Biol.* **234**, 779–815

52. Biancalana, M., and Koide, S. (2010) Molecular mechanism of thioflavin-T binding to amyloid fibrils. *Biochim. Biophys. Acta* **1804**, 1405–1412

53. Parone, P. A., Da Cruz, S., Han, J. S., McAlonis-Downes, M., Vetto, A. P., Lee, S. K., Tseng, E., and Cleveland, D. W. (2013) Enhancing mitochondrial calcium buffering capacity reduces aggregation of misfolded SOD1 and motor neuron cell death without extending survival in mouse models of inherited amyotrophic lateral sclerosis. *J. Neurosci.* **33**, 4657–4671

54. Brujin, L. I., Becher, M. W., Lee, M. K., Anderson, K. L., Jenkins, N. A., Copeland, N. G., Sisodia, S. S., Rothstein, J. D., Borchelt, D. R., Price, D. L., and Cleveland, D. W. (1997) ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. *Neuron* **18**, 327–338

55. Caggery, B., and Lansbury, P. T. (2003) Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. *Annu. Rev. Neurosci.* **26**, 267–298

56. Banerjee, V., and Das, K. P. (2012) Modulation of pathway of insulin fibrillation by a small molecule helix inducer 2,2,2-trifluoroethanol. *Colloids Surf. B. Biointerfaces* **92**, 142–150

57. Brettschneider, J., Del Tredici, K., Lee, V. M., and Trojanowski, J. Q. (2015) Neuron-related amyloid: a link to toxic effects of calcium overload in amyotrophic lateral sclerosis. *Neurobiol. Dis.* **59**, 8–19

58. Pratt, A. J., Shin, D. S., Merz, G. E., Rambo, R. P., Lancaster, W. A., Dyer, K. N., Bailer, P. P., Poole, F. L., 2nd, Adams, M. W., Freed, J. H., Crane, B. R., Tainer, J. A., and Getzoff, E. D. (2014) Aggregation propensities of proteins†.

59. Shibata, N., Hirano, A., Kobayashi, M., Siddique, T., Deng, H.-X., Hung, W.-Y., Kato, T., and Asayama, K. (1996) Intense superoxide dismutase-1 (SOD1) expression in the central nervous system is associated with motor neuron cell death without extending survival in mouse models of inherited amyotrophic lateral sclerosis. *J. Biol. Chem.* **271**, 7803–7808

60. Janson, C., McPhee, S., Bilaniuk, L., Hasegawa, J., Testaiutti, M., Freese, A., Wang, D.-J., Shera, D., Hurh, P., Rupin, J., Saslow, E., Goldfarb, O., Goldberg, M., Larijani, G., Sharrar, W., et al. (2002) Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. *Hum. Gene Ther.* **13**, 1391–1412

61. Marks, W. J., Jr., Ostrem, J. L., Verhagen, L., Starr, P. A., Larson, P. S., Bakay, R. A., Taylor, R., Cahn-Weiner, D. A., Stoessl, A. I., Llanow, C. W., and Bartus, R. T. (2008) Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson’s disease: an open-label, phase 1 trial. *Lancet Neurol.* **7**, 400–408

62. Worgall, S., Sondhi, D., Hackett, N. R., Kososofsky, B., Kekatpure, M. V., Neyzi, N., Dyke, J. P., Ballon, D., Heier, L., Greenwald, B. M., Christos, P., Mazumdar, M., Souweidane, M. M., Kaplitt, M. G., and Crystal, R. G. (2008) Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adenovirus-associated virus expressing CLN2 cDNA. *Hum. Gene Ther.* **19**, 463–474

63. Patel, P., Krich, J., Gravel, M., Soucy, G., Barell, C., Gravel, C., and Julien, J. P. (2011) AAV-mediated delivery of a recombinant single-chain antibody against misfolded superoxide dismutase for treatment of amyotrophic lateral sclerosis. *Mol. Ther.* **22**, 498–510

64. Humphrey, W., Dalke, A., and Schulten, K. (1996) VMD: visual molecular dynamics. *J. Mol. Graph.* **14**, 33–38

65. Phillips, J. C., Braun, R., Wang, W., Gumbart, J., Tajkhorshid, E., Villa, E., Chipot, C., Skeel, R. D., Kale, L., and Schulten, K. (2005) Scalable molecular dynamics with NAMD. *J. Comput. Chem.* **26**, 1781–1802

66. Mackrell, A. D., Bashford, D., Bellott, M., Dunbrack R. L., Evans, E. D., Field, M. J., Fischer, S., Gao, J., Guss, H. A., Joseph-McCarthy, D., Kuchin, L., Kuczer, K., Lau, F. T., Mattos, C., et al. (1998) All-atom empirical potential for molecular modeling and dynamics studies of protein†. *J. Phys. Chem. B* **102**, 3586–3616

67. Rosenfeld, L., Shirian, J., Zur, Y., Levaot, N., Shifman, J. M., and Papo, N. (2015) Combinatorial and computational approaches to identify interactions of macrophage colony stimulating factor (M-CSF) and its receptor c-Flm. *J. Biol. Chem.* **290**, 26180–26193

68. Cohen, I., Kayode, O., Hockla, A., Sankaran, B., Radisky, D. C., Radisky, E. S., and Papo, N. (2016) Combinatorial protein engineering of proteolytically resistant mesotrypsin inhibitors as candidates for cancer therapy. *Biochem. J.* **473**, 1329–1341

69. Rosenfeld, L., Heyne, M., Shifman, J. M., and Papo, N. (2016) Protein Engineering by combined computational and in vitro evolution approaches. *Trends Biochem. Sci.* **41**, 421–433

70. Lovell, S. C., Davis, I. W., Arendall, W. B., 3rd, de Bakker, P. I., Word, J. M., Prisant, M. G., Richardson, J. S., and Richardson, D. C. (2003) Structure validation by Ca geometry: ϕ, ψ, and Cβ deviation. *Proteins* **50**, 437–450

71. Bowie, J. U., Lüthy, R., and Eisenberg, D. (1991) A method to identify protein sequences that fold into a known three-dimensional structure. *Science* **253**, 164–170

72. Brooks, B. R., Brooks, C. L., 3rd, Walker, J. M., Drabik, J. C., Aguilar-Benavides, R., Zou, B., Woods, R. S., Hodge, M. R., Darden, T. A., Otto, C. L., and Brooks, D. J. (2000) CHARMM: the biomolecular simulation program. *J. Comput. Chem.* **21**, 1687–1720

73. Chen, R., and Weng, X. (2003) A novel shape complementarity scoring function for protein-protein docking. *Proteins* **51**, 397–408

74. Pierce, B., and Weng, Z. (2007) ZRANK: reranking protein docking predictions with an optimized energy function. *Proteins* **67**, 1086–1086

75. Comeau, S. R., Gatchell, D. W., Vajda, S., and Camacho, C. J. (2004) ClustalW2: Improving the sensitivity of ClustalW for aligning protein sequences. *Trends Biochem. Sci.* **29**, 958–960

76. Lorenzen, S., and Zhang, Y. (2007) Identification of near-native structures by clustering protein docking conformations. *Proteins* **68**, 187–194

77. Banerjee, V., Kar, R. K., Datta, A., Parthasarathi, K., Chatterjee, S., Das, K. P., and Bhunia, A. (2013) Use of a small peptide fragment as an inhibitor of insulin fibrillation process: a study by high and low resolution spectroscopy. *PloS ONE* **8**, e72318

78. Wang, Y., McGivern, D. R., Cheng, L., Li, G., Lemon, S. M., Niu, J., Su, L., and Reszka-Blanco, N. J. (2015) Ribavinbin contributes to hepatitis C virus suppression by augmenting pDC activation and type I IFN production. *PloS ONE* **10**, e0135232